MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

170.36
+2.51
+1.50%
After Hours: 169.69 -0.67 -0.39% 16:36 01/17 EST
OPEN
169.00
PREV CLOSE
167.85
HIGH
171.91
LOW
167.53
VOLUME
350.79K
TURNOVER
--
52 WEEK HIGH
210.35
52 WEEK LOW
113.01
MARKET CAP
10.40B
P/E (TTM)
-12.3048
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BGNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BGNE News

  • 9 Takeaways From The JPMorgan Healthcare Conference
  • Benzinga.14h ago
  • Morgan Stanley Reinstates Overweight on BeiGene, Announces $210 Price Target
  • Benzinga.21h ago
  • BeiGene in-licences candidates from EUSA Pharma
  • Seeking Alpha - Article.4d ago
  • EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA® in Greater China
  • GlobeNewswire.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About BGNE

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More

Webull offers Beigene Ltd (ADR) (BGNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.